Introduction
============

Maintenance medications are drugs prescribed to patients over a long period of time in order to treat chronic conditions such as diabetes, hypertension, heart disease, and depression.[@b1-ppa-11-373] However, when researchers study patients' use of maintenance medications over time, they note that within the first 6 months a significant number of patients in the US become nonadherent to their prescribed treatment.[@b2-ppa-11-373] The World Health Organization (WHO) estimates that the average rate of nonadherence among patients in the US with one or more chronic conditions is \~50%.[@b1-ppa-11-373] Furthermore, patients with multiple chronic conditions are more likely to be nonadherent.[@b3-ppa-11-373]

Increasing adherence to maintenance medications benefits both patients and the health care system. First, adherent patients experience a reduction in mortality risks.[@b4-ppa-11-373] Second, they are less likely to be hospitalized and use the emergency room and are therefore protected from unexpected health care cost.[@b5-ppa-11-373]--[@b8-ppa-11-373] Third, with an increasingly adherent patient population, the health care system becomes more cost-efficient.[@b3-ppa-11-373],[@b5-ppa-11-373],[@b9-ppa-11-373]

Patients become nonadherent to their medication regimen due to a complex set of observable and unobservable dimensions,[@b6-ppa-11-373],[@b8-ppa-11-373] including those related to the health care system,[@b10-ppa-11-373]--[@b12-ppa-11-373] the specific medication therapy,[@b12-ppa-11-373] the chronic condition,[@b13-ppa-11-373] and patients' unique psychological and cognitive factors.[@b14-ppa-11-373]

Medicare beneficiaries, comprised of the elderly (aged ≥65 years) and the disabled, obtain comprehensive drug coverage from privately covered prescription drug plans -- Medicare Part D plans.[@b15-ppa-11-373]--[@b17-ppa-11-373] However, even though Medicare Part D beneficiaries pay a lower cost for maintenance medications, many are still nonadherent.[@b18-ppa-11-373] Forgetfulness[@b18-ppa-11-373] and concerns about medication effectiveness and side effects[@b19-ppa-11-373] are the primary reasons for nonadherence in this patient population.

We focus on adherence in the Medicare Part D patient population since an incremental improvement in the adherence level of these patients can, in turn, not only reduce the risk of hospitalization and unexpected medical spending for patients but also increase the star quality rating of Medicare Part D plans. In particular, the star rating computation heavily weighs patient adherence to antidiabetic, antihypertensive, and antihyperlipidemic medications.[@b16-ppa-11-373] A higher star rating -- annually assigned by the Centers for Medicare and Medicaid Services (CMS)[@b16-ppa-11-373] -- increases the potential profitability of individual Medicare Part D plans with higher payments from the CMS[@b16-ppa-11-373],[@b17-ppa-11-373] and increased beneficiary enrollment throughout the year.[@b20-ppa-11-373],[@b21-ppa-11-373]

Since pharmacists and pharmacy staff frequently interact with their patients and establish strong pharmacist-to-patient relationships, they are uniquely positioned to address their patient's medication concerns and help improve adherence.[@b22-ppa-11-373],[@b23-ppa-11-373] Moreover, while physicians play a significant role counseling their patients on adherence to medications, they are often ill-equipped in identifying nonadherence.[@b22-ppa-11-373],[@b23-ppa-11-373] In contrast, pharmacies have access to prescription refill information, which is a reliable source of data to identify nonadherence.

In fact, pharmacies have implemented tailored interventions to improve adherence among their patients with chronic conditions.[@b24-ppa-11-373],[@b25-ppa-11-373] To address forgetfulness, some pharmacies offer omnichannel (pharmacy telephone calls, automated calls, emails, text messages, etc) refill reminders that include automated refill reminders, pickup reminders, and late-to-refill (LTR) reminders.[@b6-ppa-11-373]

This study evaluates the efficacy of a nationwide pharmacy chain's LTR reminder program, which entails local pharmacists placing reminder calls to Medicare Part D patients who are late in refilling their maintenance medication(s) on patient's adherence and persistence to medication. We hypothesize that LTR calls placed by pharmacists will significantly increase medication adherence among Medicare Part D patients.

Methods
=======

We conducted a randomized controlled study to measure the impact of the LTR reminder calls on adherence. This study, including a waiver of consent, was approved by Quorum Institutional Review Board Protocol \# 29081.

Data sources and patient election
---------------------------------

Study participants included all Walgreens Medicare Part D patients in the US who were 3 days late in refilling their maintenance medication between January 1, 2015, and January 31, 2015. We collected their pharmacy claims data from July 2014 through January 2016. Participants were randomly assigned to receive the LTR reminder call intervention or to a usual care control group (ie, no reminder calls).

Intervention
------------

Pharmacists conducted LTR calls from more than 8,000 Walgreens' locations in communities across the US. During the call, pharmacists reminded patients that they are late for a refill and offered to refill their prescription. Pharmacists also asked patients about their barriers to adherence and informed them about various programs to support their adherence such as email and text refill reminders, smartphone apps, script alignment, and 90-day prescriptions. If patients were overdue for multiple maintenance medication refills, they were reminded of all medication refills due during one phone call. Each time a patient was late for a refill, pharmacists made a total of three attempts to reach the patient by phone over a 3-day period. Control patients became eligible to receive LTR calls from April 2016. Patients were not excluded if they were eligible or participating in other pharmacy intervention programs. On average, patients were late to refill their maintenance medications \~2.3 times during the study period.

Outcomes assessment
-------------------

We measured adherence outcomes within a month of the expected refill date and after 1 year. To assess the short-term impact of the program, we calculated the refill rate as the percentage of prescriptions refilled within 7, 14, and 30 days after the expected refill date.

To evaluate the 1-year adherence, we calculated three outcome measures: 1) the proportion of days covered (PDC) as a continuous measure, 2) the PDC as a categorical measure, and 3) persistence.

PDC measures are defined at the drug class level using the Generic Product Identifier (GPI) six-digit level from a standard hierarchical drug classification system -- the Medi-Span™ Master Drug Database (Wolters Kluwer Health Inc, Conshohocken, PA, USA). The GPI is a 14-digit code that helps identify pharmaceutical drugs with the same active ingredients, dosage, and strength.[@b26-ppa-11-373] The first six digits (GPI-6) of the GPI combine pharmaceutically equivalent drugs together at the therapeutic subclass level.[@b26-ppa-11-373]

We defined the PDC as the number of days patients were in possession of their medication over 365 days from the index date. The index date is the sold date for the prescription that triggered the LTR reminder call in January 2015.

The continuous PDC measure can range from nearly 0% to 100%; the greater the value, the better the adherence. The categorized PDC measure distinguishes patients who are nonadherent (PDC \<50%), partially adherent (50% ≤ PDC \<80%), and adherent (PDC ≥80%). The PDC thresholds used to classify patients closely follow the thresholds used by previous adherence studies.[@b10-ppa-11-373],[@b27-ppa-11-373],[@b28-ppa-11-373]

Persistence is measured as the duration of days from initiation to discontinuation of maintenance medication over a 270-day period. Discontinuation is defined as a failure to refill medications within 90 days of the expected refill date.

We compared differences in the outcome measures between the intervention and control groups. Student's *t*-tests were used to evaluate significant differences in continuous PDC and persistence. Chi-squared tests were used to assess the statistical significance of the differences in refill rates and the share of patients within specific PDC categories (adherent, partially adherent, and nonadherent). All data analyses were performed with SAS 9.3 software (SAS Institute Inc., Cary, NC, USA).

Results
=======

Across the 1-year study period, 735,218 Medicare Part D patients who were 3 days overdue were placed on a contact list for LTR reminder calls. Of these patients, 367,631 were randomly assigned to the intervention group and 367,587 were randomly assigned to the control group.

Results in [Table 1](#t1-ppa-11-373){ref-type="table"} display the baseline characteristics of patients in the intervention and control groups. Baseline patient characteristics in both groups were similar. For instance, more than 60% of the patients were female, \~70 years of age, and took \~4 medications over a 6-month period. There were also no significant differences in comorbidities between patients in the two groups at baseline since a majority of the medications purchased by both groups were similar. Since the observable baseline demographic and health characteristics are not significantly different, these results validate that randomization was achieved.

Trends in [Figure 1](#f1-ppa-11-373){ref-type="fig"} and [Table 2](#t2-ppa-11-373){ref-type="table"} show that the cumulative refill rate was significantly higher in the intervention group by an average of 3.8 percentage points within the first 7 days and 6.1 percentage points within the first 14 days after the expected refill date (*P*\<0.001). The cumulative refill rate was significantly higher in the intervention group by an average of 4.4 percentage points within the first 30 days after the expected refill date (*P*\<0.001).

Furthermore, comparing the cumulative refill rates over a 30-day follow-up period between the intervention and control groups by their top 10 therapeutic classes shows that the LTR reminder calls significantly increased refill rates across all therapeutic classes ranging from 3.4 to 5.2 percentage points (*P*\<0.001; [Table 3](#t3-ppa-11-373){ref-type="table"}).

PDC and persistence
-------------------

Results in [Table 4](#t4-ppa-11-373){ref-type="table"} illustrate that the mean PDC in the intervention group significantly increased by 0.9 percentage points relative to the control group (*P*\<0.001). Furthermore, results in [Table 5](#t5-ppa-11-373){ref-type="table"} confirm the number of nonadherent patients (PDC \<50%) in the intervention group was significantly lower than the control group by 1.1 percentage points (*P*\<0.001). In contrast, the number of adherent patients (PDC ≥80%) in the intervention group was significantly greater than the control group by 1.0 percentage points (*P*\<0.001).

Persistence in a 270-day follow-up period with a 90-day discontinuation gap in the intervention group was significantly (*P*\<0.001) higher than that in the control group by 2.2 days ([Table 6](#t6-ppa-11-373){ref-type="table"}). Since the optimal discontinuous gap period may vary in accordance to clinical relevance and there is no consensus on the average permissible gap period in the literature,[@b29-ppa-11-373] we tested if results changed using a 120-day discontinuation gap period. We found that the average persistency difference between intervention and control group patients was robust and did not change.

Discussion
==========

Approximately 32% of Medicare Part D patients are nonadherent to their diabetes, hypertension, and cholesterol medications.[@b30-ppa-11-373] Patient forgetfulness and misconceptions about the risk of side effects are potential drivers of nonadherence in this population.[@b31-ppa-11-373],[@b32-ppa-11-373] Local pharmacists can nudge patients to increase adherence since they can remind them to refill medications on time and address their concerns about their medications.[@b18-ppa-11-373],[@b19-ppa-11-373],[@b22-ppa-11-373],[@b23-ppa-11-373],[@b32-ppa-11-373]

We conducted a randomized study of an LTR medication reminder program within the Medicare Part D population. Using pharmacy claims data, we evaluated each patient's medication utilization over 1 year. Results confirmed that in the Medicare Part D population, LTR reminder calls from local pharmacists significantly increased the cumulative refill rate of their maintenance medications across a variety of therapeutic classes by an average of 22.8% (6.09 percentage points) within the first 14 days after being due for a refill. LTR reminder calls increased average PDC by 1.5% (0.856 percentage points) over a 1 year period and persistence by 2.2 days over a period of 270 days. The results suggest that sustained reminder calls placed by the local pharmacist to Medicare Part D patients, who are late for refills, can improve refill rates in the short term and lead to increased adherence and persistence in the long term.

Adherence measured by PDC tends to be higher in the Medicare Part D population than in the commercial insurance population.[@b33-ppa-11-373] However, since this study included only Medicare Part D patients who were already late for a refill, the PDC of the study cohort is lower than the average PDC that we generally observe in the Medicare Part D population.

Previous studies have evaluated the impact of innovative pharmacy programs at increasing adherence and found encouraging results.[@b6-ppa-11-373],[@b24-ppa-11-373],[@b32-ppa-11-373] However, a number of these studies evaluated the impact of a multifaceted set of interventions on adherence. Patients in both intervention and control groups in our study may have received a variety of pharmacy interventions. We focused on the impact of the pharmacist LTR reminder calls on adherence. In addition, the robustness of the findings reported in the literature is relatively weak since a majority of the studies were observational. In comparison, our results are based on a randomized controlled study allowing us to conclude with confidence that increased adherence was attributable to the intervention and not unobserved factors.[@b34-ppa-11-373] Furthermore, given the broad geographic footprint of Walgreens, participants in the present study were representative of the US population. Across the US, there are larger regional variations in adherence among patients in Medicare Part D plans relative to patients in commercial insurance plans,[@b33-ppa-11-373] but most of the previous studies are not representative of the US Medicare population and have therefore been unable to control for this variability.

Still, our study has some limitations. First, we are unable to distinguish patients who are nonadherent to their medications from those who switched pharmacies, switched plans, dropped out of Medicare Part D, or died. Second, we are unable to assess the long-term impact of LTR reminder calls on the intervention population beyond 1 year. Third, our study focuses on Medicare Part D patients and may not generalize other patient populations.

Nonetheless, our findings are relevant for Medicare Part D insurance plans. Our study shows that for Medicare Part D patients who exhibited nonadherent behavior -- not refilling at least 3 days from the expected January refill date -- an LTR reminder call increased the number of adherent patients (PDC ≥80%) by \~3% (0.97 percentage points). This incremental improvement in patient adherence can have significant implications on Medicare Part D plans, the star rating, and their associated financial impact. Consequently, the LTR reminder call intervention has the potential to improve the star ratings of Medicare Part D plans.

Conclusion
==========

Using a randomized controlled study, we demonstrated that refill reminder calls from a local pharmacist to patients who were 3 days late in refilling their maintenance medication significantly improved adherence in the Medicare Part D patient population. Patients who received the intervention were 1) more likely to refill their medication within the first 14 days of their expected refill date, 2) more likely to have a higher adherence (PDC) throughout a period of 365 days, and 3) more likely to persist on their medication. Within the targeted population, the intervention significantly increased the number of adherent Medicare Part D patients (PDC ≥80%) by \~3% (0.97 percentage points), including the drug classes (antidiabetics, antihypertensives, and antihyperlipidemics) that impact the CMS star rating.
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###### 

Baseline patient characteristics

  Characteristics                                                          Intervention group   Control group   *P*-value
  ------------------------------------------------------------------------ -------------------- --------------- -----------
  Number of patients                                                       367,631              367,587         
  \% Female                                                                61.0                 60.9            0.5
  Mean age                                                                 70.4                 70.4            0.4
  \# Of LTR flagged medications (defined at GPI-6 level)                   1.3                  1.3             0.2
  Number of medications (defined at GPI-6 level) per patient in 6 months   4.4                  4.4             0.6
  \% Antihypertensives                                                     48.8                 48.8            0.8
  \% Antihyperlipidemics                                                   47.6                 47.7            0.3
  \% Beta blockers                                                         32.4                 32.5            0.5
  \% Antidepressants                                                       28.6                 28.5            0.2
  \% Diuretics                                                             25.4                 25.5            0.4
  \% Antidiabetics                                                         24.4                 24.2            0.1
  \% Calcium channel blockers                                              23.3                 23.3            0.8
  \% Thyroid agents                                                        17.7                 17.6            0.3
  \% Anticonvulsants                                                       17.6                 17.5            0.8
  \% Antiasthmatic and bronchodilator agents                               12.7                 12.7            0.4

**Notes:** LTR -- Medications that are late for a refill for at least 3 days. GPI-6 -- The GPI is a 14-digit code that helps identify pharmaceutical drugs with the same active ingredients, dosage, and strength. The first six digits (GPI-6) of the GPI combine pharmaceutically equivalent drugs together at the therapeutic subclass level.

**Abbreviations:** LTR, late-to-refill; GPI, Generic Product Identifier.

###### 

Cumulative refill rate

  Days from expected refill date   Cumulative refill rate (%)   Difference (percentage points)   
  -------------------------------- ---------------------------- -------------------------------- ----------------------------------------------------
  7                                16.5                         12.7                             3.8[\*\*\*](#tfn4-ppa-11-373){ref-type="table-fn"}
  14                               32.8                         26.7                             6.1[\*\*\*](#tfn4-ppa-11-373){ref-type="table-fn"}
  30                               46.1                         41.8                             4.4[\*\*\*](#tfn4-ppa-11-373){ref-type="table-fn"}

**Notes:** Chi-square tests used to evaluate whether differences are significant between intervention and control groups.

*P*-value \<0.001.

###### 

Cumulative refill rate over a 30-day follow-up period by therapeutic class

  Therapeutic class[a](#tfn5-ppa-11-373){ref-type="table-fn"}   Intervention group   Control group   Difference (percentage points)          
  ------------------------------------------------------------- -------------------- --------------- -------------------------------- ------ ----------------------------------------------------
  Antiasthmatic and bronchodilator agents                       19,916               36.5            20,017                           31.3   5.2[\*\*\*](#tfn6-ppa-11-373){ref-type="table-fn"}
  Antidepressants                                               40,520               46.5            40,142                           41.9   4.7[\*\*\*](#tfn6-ppa-11-373){ref-type="table-fn"}
  Antidiabetics                                                 34,087               47.2            34,102                           42.7   4.6[\*\*\*](#tfn6-ppa-11-373){ref-type="table-fn"}
  Antihyperlipidemics                                           55,160               51.8            55,670                           47.2   4.6[\*\*\*](#tfn6-ppa-11-373){ref-type="table-fn"}
  Diuretics                                                     25,913               44.6            26,253                           40.2   4.4[\*\*\*](#tfn6-ppa-11-373){ref-type="table-fn"}
  Antihypertensives                                             56,423               51.4            56,870                           47.3   4.1[\*\*\*](#tfn6-ppa-11-373){ref-type="table-fn"}
  Beta blockers                                                 32,391               50.5            32,363                           46.6   3.9[\*\*\*](#tfn6-ppa-11-373){ref-type="table-fn"}
  Thyroid agents                                                18,873               54.2            18,649                           50.3   3.9[\*\*\*](#tfn6-ppa-11-373){ref-type="table-fn"}
  Anticonvulsants                                               20,920               43.3            20,975                           39.5   3.8[\*\*\*](#tfn6-ppa-11-373){ref-type="table-fn"}
  Calcium channel blockers                                      23,501               51.6            23,587                           48.2   3.4[\*\*\*](#tfn6-ppa-11-373){ref-type="table-fn"}

**Notes:**

Top 10 therapeutic classes by volume. Chi-square tests used to evaluate whether differences are significant between intervention and control group.

*P*-value \<0.001.

###### 

PDC comparison

  Group                            Number of Rxs   Mean PDC (%)                                         SD (%)
  -------------------------------- --------------- ---------------------------------------------------- --------
  Intervention group (n=367,631)   466,721         56.7                                                 0.3
  Control group (n=367,587)        467,448         55.8                                                 0.3
  Difference (percentage points)                   0.9[\*\*\*](#tfn8-ppa-11-373){ref-type="table-fn"}   

**Notes:** PDC -- proportion of days covered over a 365-day period from index fill.

*P*-value \<0.001.

###### 

Adherence level comparison

  Group                            \% nonadherent                                         \% partially adherent   \% adherent
  -------------------------------- ------------------------------------------------------ ----------------------- -----------------------------------------------------
  Intervention group (n=367,631)   45.1                                                   20.4                    34.5
  Control group (n=367,587)        46.2                                                   20.3                    33.5
  Difference (percentage points)   −1.1[\*\*\*](#tfn10-ppa-11-373){ref-type="table-fn"}   0.1                     1.0[\*\*\*](#tfn10-ppa-11-373){ref-type="table-fn"}

**Notes:** Chi-square tests used to evaluate whether differences are significant between intervention and control groups.

*P*-value \<0.001.

**Abbreviation:** PDC, proportion of days covered.

###### 

Persistence comparison

  Group                            \# Rxs    Mean persistence (days)                               SD (days)
  -------------------------------- --------- ----------------------------------------------------- -----------
  Intervention group (n=367,631)   466,721   182.2                                                 99.0
  Control group (n=367,587)        467,448   180.0                                                 99.8
  Difference (days)                          2.2[\*\*\*](#tfn13-ppa-11-373){ref-type="table-fn"}   

**Notes:** Persistence is measured as the duration of days from initiation to discontinuation of maintenance medication over a 270-day period.

*P*-value \<0.001).
